AMAG Pharmaceuticals Announces Preliminary Data Regarding the Safety and Efficacy of a Single Infusion of 1020 mg Ferumoxytol in Patients with Iron Deficiency Anemia

AMAG Pharmaceuticals, Inc.

today announced new clinical data for ferumoxytol (Feraheme®), the company's treatment for iron deficiency anemia in adult patients with chronic kidney disease . These data were presented on Saturday, December 10, 2011, at a poster session at the American Society of Hematology annual meeting in San Diego, CA. The overall results from the study are presented below: No serious adverse events were reported. Of the non-serious AEs reported, all resolved without therapy. Five of the 16 patients who experienced non-serious AEs had a known medication allergy. A majority of patients achieved a ≥1 g/dL rise in Hgb from Baseline: 86% at Week 4 and 87% at Week 8. A majority of patients achieved a ≥ 2 g/dL rise in Hgb from Baseline: 61% at Week 4 and 70% at Week 8. The pattern regarding red blood cell distribution through Week 8 was reflective of an ongoing hematopoietic response: 16.5% at Baseline, 20.2% at Week 4, and 19.0% at Week 8.